Rishi Raj, MD
Critical Care (Intensivists) · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 1
- 1 carrier
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
1 plan · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Raj’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C148274 · Current
Licensed to practise in California · since 2017 · expires 2027-03-31 · Tamil Nadu Dr. M.G.R. Medical University, Christian Medical College, Vellore.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Illinois 036131528Licensed Physician And Surgeon · since 2012 · expires 2017-07-31Not RenewedNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$44,891
Medicare paid this office $44,891 for 141 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Critical care, first 30-74 minutes | 78 | $35,296 | $185 |
| Long return visit (40+ min) | 42 | $5,296 | $113 |
Who their Medicare patients are
141 Original Medicare patients in 2024. Average age 72 · Women 55% · Also on Medicaid 34% · Health risk score 2.44. Above the middle of the specialty; the typical pulmonary disease clinician is at 2.13.
Conditions among them: High blood pressure 75% · Heart failure 33% · Chronic kidney disease 33% · Coronary heart disease 32% · Atrial fibrillation 31% · Stroke 31% · COPD 30% · Diabetes 28% · Cancer 24% · Depression 18% · Dementia 16%.
The office billed $382,779, Medicare allowed $57,331 and paid $44,891; for 282 services of 14 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 141 | 282 | 72 | 2.44 | $382,779 | $44,891 |
| 2023 | 214 | 542 | 73 | 2.85 | $757,199 | $90,541 |
| 2022 | 191 | 403 | 74 | 2.25 | $457,223 | $65,221 |
| 2021 | 231 | 564 | 74 | 1.69 | $274,345 | $60,200 |
| 2020 | 177 | 414 | 74 | 2.19 | $252,718 | $44,278 |
| 2019 | 286 | 534 | 74 | 2.15 | $110,572 | $39,584 |
| 2018 | 540 | 1,210 | 72 | 2.15 | $180,856 | $56,217 |
| 2017 | 438 | 863 | 71 | 2.22 | $234,521 | $59,313 |
| 2016 | 471 | 1,208 | 70 | 2.34 | $372,126 | $88,545 |
| 2015 | 448 | 1,207 | 71 | 2.35 | $407,565 | $98,309 |
| 2014 | 359 | 1,015 | 71 | 2.36 | $366,692 | $89,516 |
| 2013 | 321 | 809 | 69 | 2.62 | $295,834 | $71,627 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Critical care, first 30-74 minutes | 117 | $72,678 | $192 |
| Long return visit (40+ min) | 73 | $10,759 | $118 |
| New patient visit (60+ min) | 18 | $2,539 | $141 |
| Critical care, each additional 30 minutes | 12 | $2,316 | $96 |
2022: 3 services
| Critical care, first 30-74 minutes | 64 | $42,149 | $196 |
| Long return visit (40+ min) | 98 | $14,777 | $117 |
| New patient visit (60+ min) | 27 | $4,675 | $173 |
2021: 7 services
| Long return visit (40+ min) | 111 | $26,697 | $149 |
| Critical care, first 30-74 minutes | 42 | $23,165 | $198 |
| New patient visit (60+ min) | 31 | $6,361 | $205 |
| Test to examine how well the lungs exchange gases | 94 | $784 | $8 |
| Test to measure expiratory airflow and volume | 85 | $655 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 18 | $174 | $10 |
| Test to determine lung volumes using sensors | 14 | $158 | $11 |
2020: 6 services
| Critical care, first 30-74 minutes | 34 | $20,970 | $204 |
| Long return visit (40+ min) | 97 | $14,225 | $99 |
| New patient visit (60+ min) | 20 | $3,060 | $153 |
| Return visit (30+ min) | 24 | $1,358 | $52 |
| Test to examine how well the lungs exchange gases | 37 | $317 | $9 |
| Test to measure expiratory airflow and volume | 35 | $278 | $8 |
2019: 13 services
| Long return visit (40+ min) | 79 | $10,797 | $98 |
| Return visit (30+ min) | 75 | $5,973 | $71 |
| New patient visit (60+ min) | 41 | $5,640 | $138 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 21 | $3,490 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,178 | $66 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,733 | $124 |
| New patient visit (45+ min) | 15 | $1,727 | $115 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 14 | $1,272 | $91 |
| Short return visit (20+ min) | 16 | $836 | $46 |
| Test to examine how well the lungs exchange gases | 42 | $350 | $8 |
| Test to measure expiratory airflow and volume | 42 | $324 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 24 | $276 | $12 |
| Test to determine lung volumes using sensors | 14 | $150 | $11 |
2018: 16 services
| Long return visit (40+ min) | 103 | $14,558 | $97 |
| New patient visit (60+ min) | 63 | $9,343 | $148 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 41 | $5,622 | $65 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 31 | $3,789 | $122 |
| Return visit (30+ min) | 42 | $3,498 | $70 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,370 | $94 |
| New patient visit (60+ min) | 17 | $2,757 | $162 |
| Test to examine how well the lungs exchange gases | 244 | $2,046 | $8 |
| Irrigation and suction of lung airways to obtain cells using an endoscope | 14 | $1,722 | $123 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 139 | $1,636 | $12 |
| New patient visit (45+ min) | 15 | $1,499 | $100 |
| Test to measure expiratory airflow and volume | 146 | $1,126 | $7 |
| Test to determine lung volumes using sensors | 93 | $1,033 | $11 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $988 | $90 |
| Test to measure expiratory airflow and volume | 36 | $297 | $7 |
| Test to determine lung volumes using gas dilution or washout | 19 | $200 | $11 |
2017: 18 services
| Critical care, first 30-74 minutes | 22 | $9,623 | $178 |
| Return visit (30+ min) | 100 | $9,061 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 53 | $8,024 | $86 |
| New patient visit (60+ min) | 40 | $6,013 | $150 |
| Long return visit (40+ min) | 38 | $4,882 | $100 |
| Long return visit (40+ min) | 23 | $3,407 | $114 |
| New patient visit (60+ min) | 20 | $3,403 | $170 |
| New patient visit (45+ min) | 26 | $3,117 | $120 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 11 | $1,994 | $181 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 14 | $1,687 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 17 | $1,298 | $62 |
| Test to examine how well the lungs exchange gases | 107 | $859 | $8 |
| Pulmonary exercise testing | 13 | $690 | $46 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 53 | $621 | $12 |
| Test to determine lung volumes using sensors | 56 | $601 | $11 |
| Test to measure expiratory airflow and volume | 65 | $477 | $7 |
| Test to measure expiratory airflow and volume | 33 | $473 | $14 |
| Test to determine lung volumes using gas dilution or washout | 13 | $135 | $10 |
2016: 18 services
| Critical care, first 30-74 minutes | 42 | $18,516 | $191 |
| Return visit (30+ min) | 125 | $14,825 | $86 |
| Long return visit (40+ min) | 69 | $14,291 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 79 | $10,908 | $88 |
| New patient visit (45+ min) | 59 | $7,973 | $135 |
| New patient visit (60+ min) | 31 | $5,291 | $171 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,407 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $2,369 | $61 |
| Pulmonary exercise testing | 37 | $1,927 | $47 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 16 | $1,732 | $108 |
| Test to examine how well the lungs exchange gases | 127 | $980 | $8 |
| Test to determine lung volumes using sensors | 78 | $802 | $10 |
| Test to examine how well the lungs exchange gases | 14 | $724 | $45 |
| Test to measure expiratory airflow and volume | 19 | $676 | $29 |
| Test to measure expiratory airflow and volume | 90 | $644 | $7 |
| Test to determine lung volumes using gas dilution or washout | 14 | $560 | $35 |
| Test to determine lung volumes using gas dilution or washout | 47 | $485 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 40 | $428 | $11 |
2015: 18 services
| Critical care, first 30-74 minutes | 70 | $32,771 | $193 |
| Long return visit (40+ min) | 71 | $15,083 | $120 |
| Return visit (30+ min) | 85 | $11,451 | $85 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 86 | $11,309 | $88 |
| New patient visit (45+ min) | 42 | $5,550 | $132 |
| New patient visit (60+ min) | 23 | $3,773 | $164 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 18 | $3,109 | $173 |
| Pulmonary exercise testing | 47 | $2,650 | $46 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $2,612 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 22 | $2,560 | $116 |
| Test to measure expiratory airflow and volume | 27 | $996 | $30 |
| Test to examine how well the lungs exchange gases | 112 | $824 | $7 |
| Test to examine how well the lungs exchange gases | 15 | $725 | $45 |
| Test to determine lung volumes using sensors | 70 | $686 | $10 |
| Test to determine lung volumes using gas dilution or washout | 15 | $561 | $35 |
| Test to measure expiratory airflow and volume | 74 | $505 | $7 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 40 | $404 | $10 |
| Test to determine lung volumes using gas dilution or washout | 40 | $393 | $10 |
2014: 15 services
| Critical care, first 30-74 minutes | 61 | $36,955 | $190 |
| Return visit (30+ min) | 81 | $10,588 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 64 | $10,120 | $87 |
| Long return visit (40+ min) | 36 | $7,352 | $113 |
| New patient visit (45+ min) | 27 | $3,662 | $136 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 38 | $3,276 | $61 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 27 | $3,182 | $118 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 16 | $2,764 | $173 |
| Pulmonary exercise testing | 38 | $2,664 | $46 |
| Test to examine how well the lungs exchange gases | 77 | $590 | $8 |
| Test to determine lung volumes using sensors | 41 | $416 | $10 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 36 | $395 | $11 |
| Administration of influenza virus vaccine | 12 | $311 | $26 |
| Test to measure expiratory airflow and volume | 43 | $303 | $7 |
| Test to determine lung volumes using gas dilution or washout | 11 | $114 | $10 |
2013: 15 services
| Critical care, first 30-74 minutes | 84 | $34,809 | $181 |
| Return visit (30+ min) | 39 | $5,391 | $87 |
| Long return visit (40+ min) | 23 | $4,459 | $121 |
| New patient visit (45+ min) | 32 | $4,385 | $137 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 40 | $4,207 | $86 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 26 | $2,966 | $114 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 26 | $2,125 | $56 |
| Pulmonary exercise testing | 24 | $1,580 | $48 |
| Test to examine how well the lungs exchange gases | 16 | $885 | $52 |
| Test to determine lung volumes using gas dilution or washout | 15 | $634 | $40 |
| Test to examine how well the lungs exchange gases | 77 | $618 | $8 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 33 | $356 | $11 |
| Test to measure expiratory airflow and volume | 46 | $318 | $7 |
| Test to determine lung volumes using sensors | 15 | $162 | $11 |
| Test to determine lung volumes using gas dilution or washout | 11 | $119 | $11 |
Medicaid work
$11,738 in 2024
Medicaid paid $11,738 for 115 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 115 | $11,738 |
| 2024 | 115 | 1 | 15 | $11,738 |
| 2023 | 267 | 1 | 20 | $30,904 |
| 2022 | 121 | 1 | 23 | $13,349 |
| 2021 | 26 | 2 | 14 | $90 |
| 2020 | 93 | 1 | 19 | $9,027 |
| 2019 | 60 | 4 | 18 | $690 |
| 2018 | 149 | 4 | 23 | $1,245 |
See the largest Medicaid services in earlier years
2023
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 267 | $30,904 |
2022
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 121 | $13,349 |
2021
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 12 | $48 |
| Diffusing capacity | 14 | $42 |
2020
| Critical care, evaluation and management of the critically ill or critically injured patient; first 30-74 minutes | 93 | $9,027 |
2019
| EVALUATION OF WHEEZING | 19 | $303 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 12 | $158 |
| Diffusing capacity | 17 | $137 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 12 | $92 |
2018
| EVALUATION OF WHEEZING | 46 | $568 |
| Diffusing capacity | 65 | $403 |
| Plethysmography for determination of lung volumes and, when performed, airway resistance | 26 | $193 |
| Spirometry, including graphic record, total and timed vital capacity, expiratory flow rate measurement(s), with or without maximal voluntary ventilation | 12 | $80 |
Drugs they prescribed that Part D paid
$1,423,312
Pharmacies billed $1,423,312 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 219) in 2024. At or below the middle of the specialty; the typical pulmonary disease clinician is at 0%.
84 generic and 135 brand-name prescriptions · $1,423,312 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ofev | 123 | $1,385,357 | $11,263 |
| Pirfenidone | 37 | $24,902 | $673 |
| Methotrexate | 13 | $714 | $55 |
Year by year
| 2024 | 219 | 32 | 0% (0) | 62% | $1,423,312 |
| 2023 | 298 | 39 | 0% (0) | 59% | $1,788,059 |
| 2022 | 365 | 49 | 0% (0) | 68% | $2,769,684 |
| 2021 | 296 | 53 | 0% (0) | 70% | $1,943,298 |
| 2020 | 389 | 50 | 0% (0) | 49% | $1,672,931 |
| 2019 | 328 | 54 | 0% (0) | 38% | $1,125,043 |
| 2018 | 299 | 67 | None | 36% | $752,996 |
| 2017 | 413 | 75 | None | 43% | $692,615 |
| 2016 | 584 | 71 | None | 44% | $901,334 |
| 2015 | 474 | 61 | None | 39% | $800,940 |
| 2014 | 312 | 43 | None | 19% | $43,152 |
| 2013 | 161 | 47 | 0% (0) | 42% | $193,376 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 6 drugs
| Ofev | 141 | $1,658,810 | $11,765 |
| Pirfenidone | 45 | $98,768 | $2,195 |
| Trelegy Ellipta | 17 | $10,787 | $635 |
| Mycophenolate Mofetil | 11 | $5,576 | $507 |
| Methotrexate | 19 | $1,166 | $61 |
| Prednisone | 18 | $185 | $10 |
2022: 6 drugs
| Ofev | 210 | $2,393,006 | $11,395 |
| Pirfenidone | 36 | $185,702 | $5,158 |
| Esbriet | 19 | $163,965 | $8,630 |
| Mycophenolate Mofetil | 16 | $6,804 | $425 |
| Methotrexate | 17 | $791 | $47 |
| Prednisone | 22 | $311 | $14 |
2021: 6 drugs
| Ofev | 149 | $1,675,895 | $11,248 |
| Esbriet | 22 | $237,543 | $10,797 |
| Mycophenolate Mofetil | 12 | $4,189 | $349 |
| Methotrexate | 20 | $822 | $41 |
| Prednisone | 30 | $391 | $13 |
| Sulfamethoxazole-Trimethoprim | 15 | $118 | $8 |
2020: 7 drugs
| Ofev | 133 | $1,414,233 | $10,633 |
| Esbriet | 23 | $225,975 | $9,825 |
| Mycophenolate Mofetil | 61 | $9,064 | $149 |
| Spiriva | 13 | $8,799 | $677 |
| Methotrexate | 25 | $930 | $37 |
| Prednisone | 39 | $367 | $9 |
| Sulfamethoxazole-Trimethoprim | 35 | $110 | $3 |
2019: 7 drugs
| Ofev | 106 | $1,060,386 | $10,004 |
| Mycophenolic Acid | 14 | $6,867 | $490 |
| Mycophenolate Mofetil | 58 | $6,202 | $107 |
| Azathioprine | 32 | $1,055 | $33 |
| Methotrexate | 12 | $831 | $69 |
| Prednisone | 33 | $513 | $16 |
| Sulfamethoxazole-Trimethoprim | 35 | $191 | $5 |
2018: 6 drugs
| Ofev | 77 | $729,166 | $9,470 |
| Advair Diskus | 12 | $4,719 | $393 |
| Mycophenolate Mofetil | 34 | $2,787 | $82 |
| Prednisone | 44 | $520 | $12 |
| Omeprazole | 14 | $279 | $20 |
| Sulfamethoxazole-Trimethoprim | 61 | $242 | $4 |
2017: 13 drugs
| Esbriet | 56 | $472,542 | $8,438 |
| Ofev | 19 | $166,508 | $8,764 |
| Spiriva | 17 | $9,831 | $578 |
| Breo Ellipta | 20 | $9,484 | $474 |
| Advair Diskus | 18 | $7,547 | $419 |
| Symbicort | 14 | $4,375 | $312 |
| Azathioprine | 15 | $1,228 | $82 |
| Mycophenolate Mofetil | 16 | $1,197 | $75 |
| Fluticasone Propionate | 35 | $451 | $13 |
| Prednisone | 32 | $377 | $12 |
| Omeprazole | 19 | $309 | $16 |
| Sulfamethoxazole-Trimethoprim | 65 | $271 | $4 |
| Montelukast | 16 | $139 | $9 |
2016: 14 drugs
| Esbriet | 80 | $650,335 | $8,129 |
| Ofev | 22 | $186,794 | $8,491 |
| Spiriva | 36 | $14,597 | $405 |
| Symbicort | 42 | $14,081 | $335 |
| Advair Diskus | 15 | $6,623 | $442 |
| Mycophenolate Mofetil | 13 | $1,258 | $97 |
| Azathioprine | 33 | $1,151 | $35 |
| Proair Hfa | 12 | $659 | $55 |
| Prednisone | 45 | $596 | $13 |
| Fluticasone Propionate | 53 | $546 | $10 |
| Sulfamethoxazole-Trimethoprim | 64 | $357 | $6 |
| Omeprazole | 20 | $350 | $17 |
| Azithromycin | 15 | $249 | $17 |
| Alendronate | 13 | $112 | $9 |
2015: 17 drugs
| Esbriet | 65 | $510,927 | $7,860 |
| Ofev | 30 | $243,620 | $8,121 |
| Atovaquone | 13 | $13,182 | $1,014 |
| Symbicort | 25 | $7,130 | $285 |
| Mycophenolate Mofetil | 23 | $2,554 | $111 |
| Qvar | 12 | $2,245 | $187 |
| Tacrolimus | 11 | $1,627 | $148 |
| Proair Hfa | 15 | $779 | $52 |
| Azathioprine | 18 | $705 | $39 |
| Omeprazole | 35 | $425 | $12 |
| Prednisone | 30 | $422 | $14 |
| Fluticasone Propionate | 27 | $243 | $9 |
| Sulfamethoxazole-Trimethoprim | 39 | $236 | $6 |
| Montelukast | 13 | $184 | $14 |
| Amlodipine Besylate | 12 | $66 | $5 |
| Pantoprazole | 12 | $64 | $5 |
| Metoprolol | 11 | $45 | $4 |
2014: 12 drugs
| Tacrolimus | 15 | $2,569 | $171 |
| Mycophenolate Mofetil | 19 | $1,609 | $85 |
| Qvar | 11 | $1,499 | $136 |
| Azathioprine | 17 | $505 | $30 |
| Prednisone | 33 | $330 | $10 |
| Fluticasone Propionate | 14 | $284 | $20 |
| Alendronate | 24 | $208 | $9 |
| Omeprazole | 13 | $160 | $12 |
| Sulfamethoxazole-Trimethoprim | 24 | $132 | $5 |
| Azithromycin | 13 | $132 | $10 |
| Pantoprazole | 12 | $70 | $6 |
| Metoprolol | 12 | $49 | $4 |
2013: 2 drugs
| Tracleer | 24 | $162,670 | $6,778 |
| Fluticasone Propionate | 11 | $234 | $21 |
Money from drug and device companies
$402 in 2025
| 2025 | 1 | 3 | None | $402 |
| 2023 | 1 | 2 | $2,883 | $2,883 |
| 2022 | 2 | 7 | $1,575 | $1,727 |
| 2021 | 1 | 1 | None | $14 |
| 2020 | 1 | 2 | $3,900 | $3,905 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Boehringer Ingelheim Pharmaceuticals | Ofev | $402 | 3 payments
|
See all 3 published payments
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-06-05 | None | $125 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-20 | Ofev | $131 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-18 | None | $147 |
See earlier years (2023, 2022, 2021, 2020)
2023: $2,883
| Boehringer Ingelheim Pharmaceuticals | Ofev | $2,883 | 2 payments
|
2022: $1,727
| Boehringer Ingelheim Pharmaceuticals | Ofev | $1,575 | 6 payments
|
| Intuitive Surgical | Da Vinci Surgical System | $153 | 1 payment
|
2021: $14
| Melinta Therapeutics | Kimyrsa | $14 | 1 payment
|
2020: $3,905
| Boehringer Ingelheim Pharmaceuticals | Ofev | $3,905 | 2 payments
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Boehringer Ingelheim Pharmaceuticals, Inc. · Outcome-Based Quantitative Radiologic Biomarkers for Ild · 2024 | Their institution | $200,000 |
| United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2024 | Their institution | $134,240 |
| E.R. Squibb & Sons, L.L.C. · A Study To Evaluate the Efficacy, Safety, and Tolerability of Bms-986278 in Participants With Idiopathic Pulmonary Fibrosis · 2025 | Their institution | $128,766 |
| United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2023 | Their institution | $121,419 |
| United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2024 | Their institution | $108,108 |
| E.R. Squibb & Sons, L.L.C. · Phase II Pulmonary Fibrosis Add-on and Treatment Nave · 2022 | Their institution | $106,680 |
| Roche Products Limited · Trial To Evaluate the Efficacy and Safety of Prm 151 in Patients With Idiopathic Pulmonary Fibrosis · 2022 | Their institution | $100,735 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Towards Outcomes-Based Quantitative Radiologic Biomarkers for Interstitial Lung Diseases · 2025 | Their institution | $100,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Outcome Based Quantitative Radiologic Biomarkers F · 2023 | Their institution | $100,000 |
| E.R. Squibb & Sons, L.L.C. · A Study To Evaluate the Efficacy, Safety, and Tolerability of Bms-986278 in Participants With Progressive Pulmonary Fibrosis · 2025 | Their institution | $96,747 |
| United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2025 | Their institution | $81,493 |
| United Therapeutics Corporation · An Open-Label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2025 | Their institution | $68,650 |
| Roche Products Limited · Ph III Ole Trial To Evaluate Long Term Safety and Efficacy of Prm 151 in Patients With Ipf · 2023 | Their institution | $59,230 |
| E.R. Squibb & Sons, L.L.C. · Phase II Pulmonary Fibrosis Add-on and Treatment Nave · 2023 | Their institution | $50,733 |
| United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (Teton-Ppf) · 2025 | Their institution | $45,938 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2021 | Their institution | $40,448 |
| E.R. Squibb & Sons, L.L.C. · Phase II Pulmonary Fibrosis Add-on and Treatment Nave · 2021 | Their institution | $39,290 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2023 | Their institution | $38,786 |
| United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (Teton-Ppf) · 2024 | Their institution | $35,742 |
| Roche Products Limited · Trial To Evaluate the Efficacy and Safety of Prm 151 in Patients With Idiopathic Pulmonary Fibrosis · 2023 | Their institution | $30,960 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2024 | Their institution | $30,899 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2020 | Their institution | $30,331 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2019 | Their institution | $22,918 |
| United Therapeutics Corporation · A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis · 2022 | Their institution | $22,492 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Pulmonary Rehabilitation and Nintedanib in Ipf · 2019 | Their institution | $14,216 |
| Celgene Corporation · Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With Idiopathic Pulmonary Fibrosis (Jk-Ipf-Pi-0004) · 2019 | Their institution | $13,056 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2022 | Their institution | $10,892 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Idiopathic Pulmonary Fibrosis Prospective Outcome Registry · 2025 | Their institution | $6,130 |
| E.R. Squibb & Sons, L.L.C. · Phase II Pulmonary Fibrosis Add-on and Treatment Nave · 2024 | Their institution | $5,531 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Pulmonary Rehabilitation and Nintedanib in Ipf · 2020 | Their institution | $4,557 |
| Boehringer Ingelheim Pharmaceuticals, Inc. · Dcri Registry Study · 2019 | This clinician | $3,335 |
| E.R. Squibb & Sons, L.L.C. · A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of Bms-986278 in Participants With Pulmonary Fibrosis · 2025 | Their institution | $3,010 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1730296575
- Licence
- CA C148274, IL 036.131528California C148274: Current · expires 2027-03-31Illinois 036131528: Not Renewed
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RC0200X (207RC0200X); Federal specialty code 207RP1001X (207RP1001X); Federal specialty code 207RS0012X (207RS0012X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2006-08-25
- NPI last updated
- 2025-02-10
- NPI record certified
- 2025-02-10
This is when the NPI record was last certified, not a medical board exam.